Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - Following the announcement that the EFZO-FIT study did not meet its primary endpoint, aTyr's stock price plummeted by 83.2%, from $6.03 to $1.02 per share in one day [2] Case Details - The complaint alleges that the defendants made positive statements while concealing material adverse facts about the drug's efficacy [2] - The primary endpoint not being met was disclosed during an investor call on September 15, 2025, leading to significant stock price decline [2] - aTyr plans to engage with the FDA to determine the next steps after the disappointing study results [2] Next Steps - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [4]

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. regarding allegations of securities fraud and unlawful business practices following disappointing clinical trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether aTyr and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request appointment as Lead Plaintiff if they purchased aTyr securities during the Class Period [2]. Group 2: Clinical Trial Results - On September 15, 2025, aTyr announced that the EFZO-FIT study, a Phase 3 trial for intravenous Efzofitimod in pulmonary sarcoidosis patients, did not meet its primary endpoint [4]. - Following the announcement of the trial results, aTyr's stock price fell by $5.01 per share, or 83.17%, closing at $1.01 per share [5]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [6].

Core Points - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [2][4] - The company's EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price from $6.03 to $1.02, a decline of 83.2% in one day [2][3] - Shareholders who purchased shares during the class period from January 16, 2025, to September 12, 2025, are encouraged to register for the class action, with a lead plaintiff deadline set for December 8, 2025 [3][4] Company Information - The Gross Law Firm is representing shareholders in the class action, emphasizing its commitment to protecting investors from deceit and fraud [4][5] - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4]

Core Viewpoint - aTyrPharma, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the efficacy of its drug candidate, Efzofitimod, during a clinical trial for pulmonary sarcoidosis [1][2]. Group 1: Allegations and Study Results - The lawsuit claims that aTyr's executives provided misleading information about the Phase 3 study's design and the drug's ability to allow patients to taper off steroids completely [2]. - On September 15, 2025, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48 [3]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in a single day [3]. Group 2: Legal Proceedings - Shareholders interested in participating in the class action must submit their papers to the court by December 8, 2025, to serve as lead plaintiff [4]. - The lead plaintiff will represent other class members in directing the litigation, but participation is not required to be eligible for recovery [4].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr plummeted by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Case Details - The complaint alleges that aTyr provided overly positive statements while concealing material adverse facts about Efzofitimod [2] - The EFZO-FIT study's failure to meet its primary endpoint was disclosed during an investor call on September 15, 2025, prompting the company to engage with the FDA for future steps [2] Next Steps - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]

Core Viewpoint - Law Offices of Frank R. Cruz is encouraging shareholders of aTyr Pharma Inc. to inquire about a potential securities fraud class action [1] Group 1 - The law firm is actively seeking shareholders of aTyr Pharma Inc. to participate in the inquiry regarding the alleged securities fraud [1] - The announcement indicates a growing concern among investors about the company's practices and potential legal implications [1]

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. regarding allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that aTyr and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request to be appointed as Lead Plaintiff if they purchased aTyr securities during the Class Period [2]. Group 2: Company Performance - On September 15, 2025, aTyr announced that its EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [4]. - Following the announcement, aTyr's stock price fell by $5.01 per share, or 83.17%, closing at $1.01 per share [5]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [6].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr plummeted by 83.2%, from $6.03 on September 12, 2025, to $1.02 on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Case Details - The complaint alleges that the defendants provided overly positive statements while concealing material adverse facts about the drug's efficacy [2] - The EFZO-FIT study's failure to meet its primary endpoint was disclosed during an investor call on September 15, 2025, prompting the stock price decline [2] - aTyr plans to engage with the FDA to determine the next steps after the disappointing study results [2] Next Steps - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant stock price decline after the company announced disappointing clinical trial results [3][4]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements about Efzofitimod while concealing material adverse facts about the drug's efficacy, particularly its ability to allow patients to taper steroid usage completely [3]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [3]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 16, 2025, to September 12, 2025, and shareholders are encouraged to register for potential lead plaintiff appointment [3][4]. - The deadline for shareholders to seek lead plaintiff status is December 8, 2025, and there is no cost or obligation to participate in the case [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [5].

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into aTyr Pharma Inc. regarding potential violations of federal securities laws, indicating possible legal challenges for the company and its investors [1]. Company Summary - aTyr Pharma Inc. is under scrutiny for its compliance with federal securities laws, which may affect investor confidence and the company's market performance [1]. - The investigation was announced following a significant event on September 15, which has not been detailed in the provided content but suggests a triggering incident for the inquiry [1].